Amneal Pharmaceuticals (NASDAQ:AMRX) Releases Earnings Results, Beats Expectations By $0.03 EPS

Amneal Pharmaceuticals (NASDAQ:AMRX) issued its quarterly earnings results on Tuesday. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.23 by $0.03, FiscalAI reports. Amneal Pharmaceuticals had a negative return on equity of 584.46% and a net margin of 5.05%. The business had revenue of $862.68 million for the quarter.

Here are the key takeaways from Amneal Pharmaceuticals’ conference call:

• Strong Q3 performance: Revenue rose 10% to $863 million, adjusted EBITDA increased 30% to $207 million, and adjusted EPS grew 53% to $0.26, prompting Amneal to raise its 2026 revenue, EBITDA, and EPS guidance.
• Affordable medicines revenue increased 19% to $547 million, supported by women’s health transdermal patches, new product launches, and biosimilar orders. The recently launched lanreotide generated approximately $7 million in late-September sales, with management expecting substantially higher revenue in Q4 and targeting 30%–40% market share.
• The completed Kashiv acquisition gives Amneal integrated biosimilar development, manufacturing, and commercialization capabilities. Management expects $400 million–$500 million of financial benefits over time and recently secured $60 million in New Jersey tax credits tied largely to biosimilar-related expansion.
• Specialty products continued to gain momentum, with CREXONT adding approximately 400 prescribers monthly and BREKIYA tracking ahead of expectations. Management expressed confidence that both products could reach the middle to high end of its long-term outlook.
• Operating cash flow guidance was reduced by $25 million at the midpoint to $325 million–$375 million because Amneal is building finished-goods inventory to meet demand and expects some collections to shift into Q1 2027. Net leverage was 3.0 times adjusted EBITDA after the Kashiv acquisition, with year-end leverage expected to rise to 3.6 times.

Amneal Pharmaceuticals Price Performance

Shares of AMRX stock traded down $0.18 during trading hours on Tuesday, hitting $20.25. 421,735 shares of the company’s stock were exchanged, compared to its average volume of 2,382,516. Amneal Pharmaceuticals has a fifty-two week low of $10.92 and a fifty-two week high of $21.68. The firm has a market cap of $6.47 billion, a P/E ratio of 41.36, a P/E/G ratio of 2.46 and a beta of 1.22. The company has a quick ratio of 1.44, a current ratio of 2.20 and a debt-to-equity ratio of 77.65. The firm has a 50 day moving average of $19.17 and a two-hundred day moving average of $15.78.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on AMRX shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $24.00 target price on shares of Amneal Pharmaceuticals in a research note on Thursday. Weiss Ratings raised shares of Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, October 8th. UBS Group reiterated a “buy” rating on shares of Amneal Pharmaceuticals in a research note on Thursday, October 1st. Barclays lifted their price objective on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Thursday, September 17th. Finally, Zacks Research raised shares of Amneal Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Monday, October 26th. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $22.86.

Insider Transactions at Amneal Pharmaceuticals

In related news, EVP Jason Daly sold 210,000 shares of Amneal Pharmaceuticals stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total value of $3,654,000.00. Following the sale, the executive vice president directly owned 35,171 shares in the company, valued at approximately $611,975.40. The trade was a 85.65% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Nikita Shah sold 146,403 shares of the business’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company’s stock, valued at approximately $4,436,858.90. This trade represents a 36.62% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 413,016 shares of company stock valued at $7,216,567 over the last 90 days. Corporate insiders own 17.30% of the company’s stock.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.